TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Degree of oculocardiac reflex (OCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nonrecurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Dyspepsia scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mannitol sensitivity (provocative dose to reach 15% drop in FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mannitol reactivity (response dose ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Salbutamol recovery post-challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of burn re-epithelialization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Balance between goal-directed and habitual control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean cross-sectional surface of dense thrombus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: total thrombus surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: platelet adhesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cure rates on day 63
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of objective progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Risk of PSA doubling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Patients' comfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Transcutaneous oxygen saturation (SaO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PaO2 /FiO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NTBV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NCV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abuse potential of tapentadol extended-release
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma concentrations of MCP-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma concentrations of RANTES
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Expression of CCR-2 and CCR-5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ADL disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: FAB score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: toxin-neutralizing antibody geometric mean concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: geometric mean fold rises
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: proportions of subjects achieving prespecified fold rises
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Risk of cardiovascular death or hospitalization for HF
Endpoint domain: Mortality/survival
Primary endpoint: patient pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for escape medication (ibuprofen)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction of pro-inflammatory cytokines in GCF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Expression of TRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Expression of VEGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: mean rhinorrhea score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean Pediatric Rhinoconjunctivitis Quality of Life Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: eosinophil representation of a posttreatment nasal smear
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum levels of total cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum levels of low-density lipoprotein cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum levels of triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum levels of non-high-density lipoprotein cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of healed teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement as defined by reduction in DAI >=3 at week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-h respiratory quotients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24-h whole-body fat oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Self-rating pain impression
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Attentional bias
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieved ripened cervix (modified Bishop score > or = 6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Height-for-age z-scores (HAZs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Body mass index-for-age z-scores (BAZs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hospital admissions due to COPD exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: velpatasvir overall exposure (AUCtau)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Willingness to pay (WTP) for diabetes SMS
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: start of renal replacement therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: CHF (Congestive Heart Failure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Colorectal cancer risk
Endpoint domain: Mortality/survival
Primary endpoint: Standardized annular area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Standardized mitral tenting volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Growth of coagulase-negative Staphylococcus colonies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Frequency of amnesia
Endpoint domain: Adverse events/effects
Primary endpoint: Dose requirement for adequate sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SDNN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of peripheral motor neuropathies, sensory neuropathies or central neurotoxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Gastric emptying half time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area under the curve for gastric emptying
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of patients positive for test species
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Distress screening performance (DT and HADS scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NIHSS score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: FM score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Cerebral blood flow auto-regulative function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cerebral vasomotoricity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cerebral hemisphere collateral circulation comprehental function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Interobserver reliability of the 24HS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of main personal goal
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: risk-standardized hospital-level rates of inotrope use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: risk-standardized length of stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: risk-standardized inpatient mortality
Endpoint domain: Mortality/survival
Primary endpoint: intention to use DMT
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: total cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of cerebral infarction
Endpoint domain: Mortality/survival
Primary endpoint: liver related outcomes
Endpoint domain: Physiological/clinical
Primary endpoint: confirmed objective partial response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumor recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Uptake of flexible sigmoidoscopy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Detection of cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean pain VAS scores at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean pain VAS scores during physiotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean overall patient satisfaction scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: pNN50
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Comfort level of loudness judgments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bioequivalence of lamotrigine products
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: interleukin-6 release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: interleukin-8 release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: C-reactive protein response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in a composite of all metrics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Petechiae
Endpoint domain: Adverse events/effects
Primary endpoint: improvement in clinical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: colon transmission time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mitral stroke volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Regurgitant volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall mortality at 28 days
Endpoint domain: Mortality/survival
Primary endpoint: VAS score for pain on blunt probing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lymphocyte beta 2-receptor density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: diastolic relaxation (rapid filling period)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: decreased eGFRcrea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: increased CKD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Endotoxin levels after CPB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL-6 concentration after CPB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in inattention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rSO2 improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hypertension or tachycardia
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in headache-related anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Dependence reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: In-hospital stay >7 days
Endpoint domain: Resource use
Primary endpoint: Surface properties deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative sensitivity
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in ICS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Shorter periods in hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Incidence of parenteral nutrition associated cholestasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IIV-RT (Intra-individual variability in reaction time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibitory control (reduction in commission errors)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MPRi-recov compared to MPRi-rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in moderate leisure physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants reaching 2.5 hours of moderate or vigorous leisure physical activity per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to amobarbital in relieving catatonic mutism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient-reported pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in case notification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in subsequent case notification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Postoperative swelling scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient rated satisfaction with surgical treatment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Active range of movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electromyogram amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of tumor control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Delivery before 37 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Pulsatility index (PI) values of RPA, LPA, and DPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Qp (pulmonary blood flow)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: DA volume blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart failure hospitalizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sympathetic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-related adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Deaths possibly related to study drug
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in levels of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Contraceptive method continuation rate at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of neonatal diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active Range of Motion (ROM) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change in visual acuity letter score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma Quality-of-Life Questionnaire (AQLQ) scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: prebronchodilator FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Morning PEF improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Evening PEF improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Long-term adherence with medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 24-hour postoperative meperidine consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: numeric rating scale score for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidences of side effects
Endpoint domain: Adverse events/effects
Primary endpoint: self-reported physical activity (PA) adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of third stage of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline plasma potassium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Development of hypokalemia
Endpoint domain: Adverse events/effects
Primary endpoint: Hip Circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse effect complaints
Endpoint domain: Adverse events/effects
Primary endpoint: Attrition owing to adverse effects
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean FAZ (Fractional Absorption of Zinc)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean TAZ (Total Absorption of Zinc)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive decline incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: collaborative communication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum [Na] from baseline to end of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients with an increase in serum [Na] of 6 mEq/L or greater
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Variability in IDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle rigidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease of the BOLD signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response in subjective well-being
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Remission concerning subjective well-being
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain at rest, during flexion, or on straight leg lift
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pain-free status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local complications of sutures
Endpoint domain: Adverse events/effects
Primary endpoint: SIGH‐SAD‐P total depression scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: moderate-to-severe posterior knee pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: moderate-to-severe anterior knee pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in yellowness (deltab*)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in lightness (deltaL*)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active ulcer-healing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Static balance performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: flare-up reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma ET-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Systemic vascular resistance index (SVRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: magnitude of hypothermia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes